Health Care · Hospital & Medical Service Plans

MOH Molina Healthcare SEC Filings & Insider Trading Activity 2026

company
CIK 1179929118 filings
S&P 500

MOH at a glance

Molina Healthcare (MOH, SEC CIK 1179929) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 22, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Molina Healthcare (MOH) reported revenue of $45.4 billion (up 11.7% from FY2024) and net income of $472.0 million. Diluted EPS was $8.92.
  • As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Molina Healthcare (MOH) shares worth $4.7 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by ORLANDO STEVEN J on November 16, 2026 of 702 shares at $227.33 per share.
  • In the last 90 days, MOH insiders reported 0 open-market purchases ($0) and 4 open-market sales ($2.3M) on Form 4, a net sale of $2.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$45.4B
+11.7% vs prior year
Insiders · 90 days
0 buys · 4 sells
Net −$2.3M
13F holders
39 funds
$4.7B · +0 vs prior quarter
Latest 8-K
Nov 6, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • Medicaid rate risk from state contracts, with top 4 states generating $17.3B, 54% of Medicaid premium revenue in 2025
  • Marketplace subsidy uncertainty due to expiration of advanced premium tax credits (APTCs) end of 2025, affecting enrollment and pricing
  • Cybersecurity risks from third-party vendors and internal access, exposing sensitive member data and risking regulatory fines or service interruptions
  • Competitive risk from contract renewals in 21 states; failure to renew could materially reduce premium revenue, 75% of consolidated premium in 2025
  • Acquisition integration risk with potential delays, cost overruns, and cultural mismatches threatening realization of expected earnings and synergies

Management Discussion & Analysis

  • Revenue $45.4B, up 12% YoY; premium revenue $43.1B, up 11% ($4.4B increase)
  • Net income $472M, down from $1,179M; operating margin 1.7% (781M/$45.4B) vs 3.9%
  • Best segment Medicaid: incremental $9B annual premium revenue new contracts; worst affected overall by 260bps MCR increase to 91.7% from 89.1%
  • Interest expense $192M up from $118M; G&A ratio 6.6% down slightly from 6.7%; capex (depreciation) $195M vs $186M; no buyback or dividend data
  • 2026 outlook includes $6B premium Florida Medicaid contract start expected Q4; growth focus on acquisitions and Medicaid expansions

Business Overview

  • Core business: Managed healthcare services focusing on Medicaid, Medicare, and Marketplace insurance segments
  • New emphasis: Significant membership growth in Marketplace (655,000 members, up 252,000 YoY) and ConnectiCare acquisition integration
  • Strategic shift: Exit from MAPD in 13 states, shifting focus to higher acuity dual-eligible Medicare populations
  • Quantitative highlight: Medical Cost Ratio (MCR) increased notably across segments; e.g., Marketplace MCR rose to 90.6% from 75.4% in 2024
  • Noteworthy fact: $1 billion new stock repurchase authorization in 2025 with $500 million repurchased plus $350 million spent on ConnectiCare acquisition

AI summary of the MOH 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $11,082M vs $11,477M YoY, down $395M
  • Net income per diluted share $0.73 vs $1.51 YoY
  • Medicaid revenue $8,199M, largest segment; Marketplace revenue unavailable for 2026 vs $1,197M YoY
  • Medical margin $2,444M for nine months vs $2,985M YoY
  • MAPD exit planned for 2027, $1.25B credit facility with no borrowings at September 30, 2026

AI summary of the MOH 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 6, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • 2026 GAAP diluted EPS guidance reaffirmed at least $2.38
  • 2026 adjusted diluted EPS guidance reaffirmed at least $5.25
Filed Oct 21, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 results cover the period ended September 30, 2026
  • Full-year 2026 earnings guidance reaffirmed, reducing risk of near-term outlook revision

Item EX-99.1: Item EX-99.1

  • Q3 adjusted EPS $0.89, down 53% YoY, as consolidated MCR rose to 92.9% from 92.6%
  • Premium revenue $10.5B, down 4% YoY, with membership falling to 4.862M from 5.628M
Filed Jul 22, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results covered quarter ended June 30, 2026
  • Full-year 2026 earnings guidance increased, signaling stronger expected profitability

Item EX-99.1: Item EX-99.1

  • Q2 adjusted EPS $1.51, down 74% year over year, as premium revenue fell 6% to $10.2 billion
  • Consolidated MCR worsened to 92.2% from 90.4%, with Medicaid 92.7% and Marketplace 88.9%

AI summaries of MOH 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MOH

Don't miss the next MOH filing

  • Alerts as it files. A push when MOH files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MOH, by share count.
  • Ask anything. An AI agent that reads every MOH filing and answers with sources.

MOH alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
ORLANDO STEVEN JSellNov 16, 2026$227.33
Zubretsky Joseph MGNov 13, 2026-
WOLF DALE BSellNov 13, 2026$206.12
Barlow Jeff D.SellNov 10, 2026$203.07
Schapiro Richard MSellNov 10, 2026$203.94
BRASIER BARBARA LAOct 1, 2026$180.85
ORLANDO STEVEN JAOct 1, 2026$180.85
ZORETIC RICHARD CAOct 1, 2026$180.85

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$40.6B$45.4B
Operating Income-$1.7B$781.0M
Net Income$1.1B$1.2B$472.0M
Op. Margin-4.2%1.7%
Net Margin-2.9%1.0%
Balance Sheet
Total Assets$14.9B$15.6B$15.6B
Equity-$4.5B$4.1B
ROE-26.2%11.6%
Per Share
EPS$18.77$20.42$8.92
Cash Flow
Operating CF-$644.0M-$535.0M
CapEx$84.0M$100.0M$101.0M

Source: XBRL data in Molina Healthcare (MOH)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MOH share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MOH shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202639$4.67B
Q2 202639$6.61B
Q1 202639$3.79B
Q4 202535$4.41B
Q3 202537$5.56B
Q2 202534$7.52B
Q1 202531$5.86B
Q4 202428$4.69B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 282 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MOH filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 16, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
8-KNov 6, 2026Analysis-
10-QOct 22, 2026Analysis
8-KOct 21, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
SC 13GSep 3, 2026-
10-QJul 23, 2026-
8-KJul 22, 2026Analysis-
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--
4Jul 2, 2026--

Related Health Care companies

All Health Care →

MOH SEC filings: frequently asked questions

Are MOH insiders buying or selling?

In the last 90 days, Molina Healthcare (MOH) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $2.3 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MOH stock?

As of September 30, 2026, the largest Molina Healthcare (MOH) holders among the 13F filers tracked by SignalX were BlackRock ($1.0 billion), AQR Capital Management ($655.2 million), Vanguard Capital Management LLC ($444.3 million), Vanguard Portfolio Management LLC ($437.5 million), State Street Corp ($321.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MOH's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Molina Healthcare (MOH) reported revenue of $45.4 billion (up 11.7% from FY2024) and net income of $472.0 million. Diluted EPS was $8.92. The figures come from the XBRL data in the 10-K.

What are the main risks in MOH's latest 10-K?

In the 10-K filed February 10, 2026, Molina Healthcare (MOH) flagged: Medicaid rate risk from state contracts, with top 4 states generating $17.3B, 54% of Medicaid premium revenue in 2025. Marketplace subsidy uncertainty due to expiration of advanced premium tax credits (APTCs) end of 2025, affecting enrollment and pricing. (AI summary of the Risk Factors section.)

What did MOH report in its latest 8-K?

Molina Healthcare (MOH) filed an 8-K on November 6, 2026 reporting Item 7.01 (Regulation FD Disclosure). 2026 GAAP diluted EPS guidance reaffirmed at least $2.38.

What are the latest MOH SEC filings?

Molina Healthcare (MOH) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 22, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on November 16, 2026.

What is MOH's SEC CIK number?

Molina Healthcare (MOH)'s SEC Central Index Key (CIK) is 1179929. EDGAR lists every MOH filing under that number.

Ask anything about MOH

The research agent reads MOH's filings, financials, insider trades and 13F holders, then answers with sources.